288 related articles for article (PubMed ID: 29634142)
21. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
22. Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database.
Lulic Z; Son H; Yoo SB; Cunnington M; Kapse P; Miller D; Cortes V; Park S; Bhak RH; Duh MS
BMC Urol; 2021 Dec; 21(1):178. PubMed ID: 34933674
[TBL] [Abstract][Full Text] [Related]
23. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
Walker A; Doyle S; Posnett J; Hunjan M
BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
[TBL] [Abstract][Full Text] [Related]
25. [Combined dutasteride and tamsulosin].
Sciarra A
Urologia; 2011; 78(4):317-9. PubMed ID: 22101551
[No Abstract] [Full Text] [Related]
26. [The effects of combination therapy with 5-reductase inhibitor and -blocker on the prognosis of BPH].
Neimark AI; Davydov AV; Aliev RT
Urologiia; 2018 May; (2):62-66. PubMed ID: 29901296
[TBL] [Abstract][Full Text] [Related]
27. [Comparative analysis of the effectiveness of early and delayed initiation of combined DRUG therapy for bph].
Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
Urologiia; 2021 May; (2):27-30. PubMed ID: 33960153
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of prostatic adenoma].
Borisov VB
Urologiia; 2010; (4):42-4. PubMed ID: 20967982
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
[TBL] [Abstract][Full Text] [Related]
30. Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.
Shindo T; Hashimoto K; Shimizu T; Itoh N; Masumori N
Korean J Urol; 2015 Apr; 56(4):305-9. PubMed ID: 25874044
[TBL] [Abstract][Full Text] [Related]
31. A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.
Udeh EI; Ofoha CG; Adewole DA; Nnabugwu II
BMC Cancer; 2016 Jul; 16():405. PubMed ID: 27388750
[TBL] [Abstract][Full Text] [Related]
32. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
[TBL] [Abstract][Full Text] [Related]
33. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacological treatment of benign prostatic hyperplasia].
Oelke M; Martinelli E
Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
[TBL] [Abstract][Full Text] [Related]
36. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
37. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
38. [Medical treatment of patients with benign prostatic hyperplasia with 5-reductase inhibitors].
Spivak LG; Platonova DV; Yagudaev DD
Urologiia; 2019 Sep; (4):175-179. PubMed ID: 31535827
[TBL] [Abstract][Full Text] [Related]
39. [Long-term outcomes of the use of α-blockers tamsulosin in men with lower urinary tract symptoms and benign prostatic hyperplasia].
Krivoborodov GG; Tur EI
Urologiia; 2014; (6):47-8, 50. PubMed ID: 25799727
[TBL] [Abstract][Full Text] [Related]
40. Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.
D'Agate S; Wilson T; Adalig B; Manyak M; Palacios-Moreno JM; Chavan C; Oelke M; Roehrborn C; Della Pasqua O
World J Urol; 2020 Feb; 38(2):463-472. PubMed ID: 31079189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
